Sanofi’s 6-in-1 childhood jab approved in EU

Markus MacGill

pharmaphorum

The European Commission has given the green light for Sanofi to market its six-in-one paediatric vaccination.

The jab, to be branded Hexyon in western Europe and Hexacima in eastern Europe, will reduce the number of immunisation visits to needed to acquire lifelong immunities. It will protect against diphtheria, tetanus, pertussis (whopping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type B.

“Hexyon/Hexacima ready-to-use, six-in-one paediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases.”

Olivier Charmeil, president and chief executive, Sanofi Pasteur.

The decision follows the European Medicines Agency’s recommendation reached on the basis of successful clinical studies involving about 5,000 infants.

&nbsp,

pharmaphorum-twitter

Related news:

Sanofi: European Commission Approved 6-in-1 Pediatric Vaccine (Fox Business)

Sanofi infant vaccine gets EU approval (Reuters)

Reference links:

Sanofi news release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.